Akari Therapeutics plc, of London, said the U.K. Medicines & Healthcare products Regulatory Agency cleared the firm to conduct a phase Ib multiple ascending-dose trial testing Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9.